Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB2 | P47870 | 5/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14167459 | 0.87 | GABRB2 (0.49) | GABRB2GABRA2KDM4EALDH1A1GAA | |
| SCHEMBL4001832 | 0.86 | CYP11B2 (0.48) | GABRB2GABRA2ALDH1A1LMNANPC1 | |
| SCHEMBL1541405 | 0.86 | GABRB2 (0.60) | GABRB2GABRA2KDM4EALDH1A1GAA | |
| SCHEMBL22717699 | 0.85 | RAB9A (0.54) | GABRB2GABRA2KDM4EALDH1A1GAA | |
| SCHEMBL16099735 | 0.83 | CYP11B2 (0.50) | GABRB2GABRA2KDM4EALDH1A1MAPK1 | |
| SCHEMBL24013805 | 0.80 | GABRG2 (0.44) | GABRB2GABRA2KDM4EALDH1A1GAA | |
| SCHEMBL899443 | 0.80 | GABRB2 (0.44) | GABRB2GABRA2ALDH1A1LMNAGABRA1 | |
| SCHEMBL30228350 | 0.80 | GABRG2 (0.44) | GABRB2GABRA2KDM4EALDH1A1GAA | |
| SCHEMBL898835 | 0.80 | GABRA1 (0.50) | GABRB2GABRA2KDM4EALDH1A1GAA | |
| SCHEMBL29276897 | 0.79 | GABRG2 (0.44) | GABRB2GABRA2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2012174164-A2 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174164-A2 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| EP-2530078-A1 | THIAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR27 | GABRB2 174/4885GABRA2 148/4885KDM4E 4629/4885 |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | GABRB2 162/4885GABRA2 354/4885KDM4E 4406/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | GABRB2 162/4885GABRA2 354/4885KDM4E 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.